Stephens Consulting’s Immunovant IMVT Stock Holding History

Stephens Consulting’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20	Closed	-$342	–	1568
2025 Q1	$342	Buy	+20	New	+$418	﹤0.01%	1380

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Stephens Consulting's IMVT Position: Q2 2025 in Review

Stephens Consulting sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 20 shares — an estimated $342 sold.

Stephens Consulting first reported a position in IMVT in Q1 2025 and held it in 1 quarter. The position peaked at $342 in Q1 2025. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

Stephens Consulting reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 20 Immunovant shares in Q2 2025, an estimated $342.
Stephens Consulting first reported a position in Immunovant in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Immunovant position peaked at $342 in Q1 2025.
168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.